Abstract 5069: Cancer immunotherapy based on the RNAi-based PD-L1 inhibitor, MN-siPDL1, demonstrates efficacy in preclinical pancreatic adenocarcinoma
Byunghee Yoo, M. Sojoodi, V. C. Jordan, P. Pantazopoulos, Subrata K. Ghosh, P. Caravan, Z. Medarova
Cancer Research